Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones

Igor A. Schepetkin, Liliya N. Kirpotina, Andrey Ivanovich Khlebnikov, Ni Cheng, Richard D. Ye, Mark T. Quinn

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) expressed on a variety of cell types. Because FPRs play an important role in the regulation of inflammatory reactions implicated in disease pathogenesis, FPR antagonists may represent novel therapeutics for modulating innate immunity. Previously, 4H-chromones were reported to be potent and competitive FPR1 antagonists. In the present studies, 96 additional chromone analogs, including related synthetic and natural isoflavones were evaluated for FPR1 antagonist activity. We identified a number of novel competitive FPR1 antagonists that inhibited fMLF-induced intracellular Ca2+ mobilization in FPR1-HL60 cells and effectively competed with WKYMVm-FITC for binding to FPR1 in FPR1-HL60 and FPR1-RBL cells. Compound 10 (6-hexyl-2-methyl-3-(1-methyl-1H-benzimidazol-2-yl)-4-oxo-4H-chromen-7-yl acetate) was found to be the most potent FPR1-specific antagonist, with binding affinity Ki ∼ 100 nM. These chromones inhibited Ca2+ flux and chemotaxis in human neutrophils with nanomolar-micromolar IC50 values. In addition, the most potent novel FPR1 antagonists inhibited fMLF-induced phosphorylation of extracellular signal-regulated kinases (ERK1/2) in FPR1-RBL cells. These antagonists were specific for FPR1 and did not inhibit WKYMVM/WKYMVm-induced intracellular Ca2+ mobilization in FPR2-HL60 cells, FPR3-HL60 cells, RBL cells transfected with murine Fpr1, or interleukin 8-induced Ca2+ flux in human neutrophils and RBL cells transfected with CXC chemokine receptor 1 (CXCR1). Moreover, pharmacophore modeling showed that the active chromones had a significantly higher degree of similarity with the pharmacophore template as compared to inactive analogs. Thus, the chromone/isoflavone scaffold represents a relevant backbone for development of novel FPR1 antagonists.

Original languageEnglish
Pages (from-to)627-641
Number of pages15
JournalBiochemical Pharmacology
Volume92
Issue number4
DOIs
Publication statusPublished - 15 Dec 2014

Fingerprint

Chromones
Formyl Peptide Receptor
Isoflavones
HL-60 Cells
human FPR1 protein
Trp-Lys-Tyr-Met-Val-Met
Interleukin-8A Receptors
Neutrophils
Fluxes
Phosphorylation
Fluorescein-5-isothiocyanate
Mitogen-Activated Protein Kinase 1
Extracellular Signal-Regulated MAP Kinases

Keywords

  • Antagonist
  • Ca mobilization
  • Formyl peptide receptor
  • Isoflavone
  • Molecular modeling
  • Neutrophil

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry
  • Medicine(all)

Cite this

Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones. / Schepetkin, Igor A.; Kirpotina, Liliya N.; Khlebnikov, Andrey Ivanovich; Cheng, Ni; Ye, Richard D.; Quinn, Mark T.

In: Biochemical Pharmacology, Vol. 92, No. 4, 15.12.2014, p. 627-641.

Research output: Contribution to journalReview article

Schepetkin, Igor A. ; Kirpotina, Liliya N. ; Khlebnikov, Andrey Ivanovich ; Cheng, Ni ; Ye, Richard D. ; Quinn, Mark T. / Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones. In: Biochemical Pharmacology. 2014 ; Vol. 92, No. 4. pp. 627-641.
@article{bbad931feccf4ccaab07769354aa248b,
title = "Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones",
abstract = "Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) expressed on a variety of cell types. Because FPRs play an important role in the regulation of inflammatory reactions implicated in disease pathogenesis, FPR antagonists may represent novel therapeutics for modulating innate immunity. Previously, 4H-chromones were reported to be potent and competitive FPR1 antagonists. In the present studies, 96 additional chromone analogs, including related synthetic and natural isoflavones were evaluated for FPR1 antagonist activity. We identified a number of novel competitive FPR1 antagonists that inhibited fMLF-induced intracellular Ca2+ mobilization in FPR1-HL60 cells and effectively competed with WKYMVm-FITC for binding to FPR1 in FPR1-HL60 and FPR1-RBL cells. Compound 10 (6-hexyl-2-methyl-3-(1-methyl-1H-benzimidazol-2-yl)-4-oxo-4H-chromen-7-yl acetate) was found to be the most potent FPR1-specific antagonist, with binding affinity Ki ∼ 100 nM. These chromones inhibited Ca2+ flux and chemotaxis in human neutrophils with nanomolar-micromolar IC50 values. In addition, the most potent novel FPR1 antagonists inhibited fMLF-induced phosphorylation of extracellular signal-regulated kinases (ERK1/2) in FPR1-RBL cells. These antagonists were specific for FPR1 and did not inhibit WKYMVM/WKYMVm-induced intracellular Ca2+ mobilization in FPR2-HL60 cells, FPR3-HL60 cells, RBL cells transfected with murine Fpr1, or interleukin 8-induced Ca2+ flux in human neutrophils and RBL cells transfected with CXC chemokine receptor 1 (CXCR1). Moreover, pharmacophore modeling showed that the active chromones had a significantly higher degree of similarity with the pharmacophore template as compared to inactive analogs. Thus, the chromone/isoflavone scaffold represents a relevant backbone for development of novel FPR1 antagonists.",
keywords = "Antagonist, Ca mobilization, Formyl peptide receptor, Isoflavone, Molecular modeling, Neutrophil",
author = "Schepetkin, {Igor A.} and Kirpotina, {Liliya N.} and Khlebnikov, {Andrey Ivanovich} and Ni Cheng and Ye, {Richard D.} and Quinn, {Mark T.}",
year = "2014",
month = "12",
day = "15",
doi = "10.1016/j.bcp.2014.09.027",
language = "English",
volume = "92",
pages = "627--641",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones

AU - Schepetkin, Igor A.

AU - Kirpotina, Liliya N.

AU - Khlebnikov, Andrey Ivanovich

AU - Cheng, Ni

AU - Ye, Richard D.

AU - Quinn, Mark T.

PY - 2014/12/15

Y1 - 2014/12/15

N2 - Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) expressed on a variety of cell types. Because FPRs play an important role in the regulation of inflammatory reactions implicated in disease pathogenesis, FPR antagonists may represent novel therapeutics for modulating innate immunity. Previously, 4H-chromones were reported to be potent and competitive FPR1 antagonists. In the present studies, 96 additional chromone analogs, including related synthetic and natural isoflavones were evaluated for FPR1 antagonist activity. We identified a number of novel competitive FPR1 antagonists that inhibited fMLF-induced intracellular Ca2+ mobilization in FPR1-HL60 cells and effectively competed with WKYMVm-FITC for binding to FPR1 in FPR1-HL60 and FPR1-RBL cells. Compound 10 (6-hexyl-2-methyl-3-(1-methyl-1H-benzimidazol-2-yl)-4-oxo-4H-chromen-7-yl acetate) was found to be the most potent FPR1-specific antagonist, with binding affinity Ki ∼ 100 nM. These chromones inhibited Ca2+ flux and chemotaxis in human neutrophils with nanomolar-micromolar IC50 values. In addition, the most potent novel FPR1 antagonists inhibited fMLF-induced phosphorylation of extracellular signal-regulated kinases (ERK1/2) in FPR1-RBL cells. These antagonists were specific for FPR1 and did not inhibit WKYMVM/WKYMVm-induced intracellular Ca2+ mobilization in FPR2-HL60 cells, FPR3-HL60 cells, RBL cells transfected with murine Fpr1, or interleukin 8-induced Ca2+ flux in human neutrophils and RBL cells transfected with CXC chemokine receptor 1 (CXCR1). Moreover, pharmacophore modeling showed that the active chromones had a significantly higher degree of similarity with the pharmacophore template as compared to inactive analogs. Thus, the chromone/isoflavone scaffold represents a relevant backbone for development of novel FPR1 antagonists.

AB - Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) expressed on a variety of cell types. Because FPRs play an important role in the regulation of inflammatory reactions implicated in disease pathogenesis, FPR antagonists may represent novel therapeutics for modulating innate immunity. Previously, 4H-chromones were reported to be potent and competitive FPR1 antagonists. In the present studies, 96 additional chromone analogs, including related synthetic and natural isoflavones were evaluated for FPR1 antagonist activity. We identified a number of novel competitive FPR1 antagonists that inhibited fMLF-induced intracellular Ca2+ mobilization in FPR1-HL60 cells and effectively competed with WKYMVm-FITC for binding to FPR1 in FPR1-HL60 and FPR1-RBL cells. Compound 10 (6-hexyl-2-methyl-3-(1-methyl-1H-benzimidazol-2-yl)-4-oxo-4H-chromen-7-yl acetate) was found to be the most potent FPR1-specific antagonist, with binding affinity Ki ∼ 100 nM. These chromones inhibited Ca2+ flux and chemotaxis in human neutrophils with nanomolar-micromolar IC50 values. In addition, the most potent novel FPR1 antagonists inhibited fMLF-induced phosphorylation of extracellular signal-regulated kinases (ERK1/2) in FPR1-RBL cells. These antagonists were specific for FPR1 and did not inhibit WKYMVM/WKYMVm-induced intracellular Ca2+ mobilization in FPR2-HL60 cells, FPR3-HL60 cells, RBL cells transfected with murine Fpr1, or interleukin 8-induced Ca2+ flux in human neutrophils and RBL cells transfected with CXC chemokine receptor 1 (CXCR1). Moreover, pharmacophore modeling showed that the active chromones had a significantly higher degree of similarity with the pharmacophore template as compared to inactive analogs. Thus, the chromone/isoflavone scaffold represents a relevant backbone for development of novel FPR1 antagonists.

KW - Antagonist

KW - Ca mobilization

KW - Formyl peptide receptor

KW - Isoflavone

KW - Molecular modeling

KW - Neutrophil

UR - http://www.scopus.com/inward/record.url?scp=84912104439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912104439&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2014.09.027

DO - 10.1016/j.bcp.2014.09.027

M3 - Review article

VL - 92

SP - 627

EP - 641

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 4

ER -